BCL2 and diffuse large B-cell lymphoma: However, a recent study showed that the PI3K/mTOR inhibitor BEZ235 can potentiate the activity of the HDAC inhibitor panobinostat in pre-clinical models of DLBCL, including DHL cell lines with overexpression of bcl-2 and MYC [12], further suggesting activation of Akt/mTOR activation in DHL.